Soterios Pharma’s STS-01 Meets Efficacy Endpoints in AA Trial
Soterios Pharma’s STS-01 performed well in mild to moderate alopecia areata, according to new Phase II data. The trial included 158 participants who were randomized to receive one of four doses of STS-01 (0.25%, 0.5%, 1% or 2%) or placebo, with effect being measured based on improvement in the SALT score. At 24 weeks, 75.9% […]